AOD-9604

AOD-9604 is a synthetic fragment based on the C-terminal portion of human growth hormone. It was developed on the premise that the fat-metabolism-related activity of growth hormone could be separated from its other effects.

It reached human clinical trials for obesity and did not demonstrate the weight-loss effect those trials were designed to detect. Later interest shifted toward cartilage and joint applications, where the published work is earlier-stage. The negative obesity result is the most substantial human evidence about this compound and is frequently left out of summaries of it.

Lipolysis and fat metabolism, where human trials did not confirm the hypothesis, and more recently cartilage repair, where the work is preliminary.

The obesity trials reported a tolerability profile without notable safety signals at the doses studied. That is a statement about tolerability in those trials, not about long-term use.

Supplied as a lyophilised powder. Reconstituted material is generally refrigerated; stability beyond short periods is not well characterised.